Biodexa Pharmaceuticals (NASDAQ:BDRX) Posts Earnings Results

Biodexa Pharmaceuticals (NASDAQ:BDRX) issued its quarterly earnings data on Friday. The company reported $0.70 earnings per share for the quarter, reports.

Biodexa Pharmaceuticals Stock Down 0.9%

Shares of NASDAQ:BDRX opened at $0.65 on Friday. The business’s 50-day moving average is $1.25 and its 200 day moving average is $3.90. Biodexa Pharmaceuticals has a 1 year low of $0.65 and a 1 year high of $19.30.

Biodexa Pharmaceuticals’s stock is going to reverse split on the morning of Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, April 3rd.

Hedge Funds Weigh In On Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC bought a new position in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned approximately 14.71% of Biodexa Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 17.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on BDRX. Wall Street Zen raised shares of Biodexa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.